Sravan Kumar¹*, R Yashaswini², Prashanthi Gundlapally³ and Sireesha Althapu⁴

¹Department of Clinical Operations, Archeron Clinical Solutions, India
²Pharm-D, Nirmala college of Pharmacy, India
³Clinical Research Associate, Teva Pharmaceuticals, India
⁴Clinical Research Coordinator, IQVIA, India

*Corresponding Author: Sravan Kumar, Department of Clinical Operations, Archeron Clinical Solutions, India.

Received: January 31, 2022; Published: February 18, 2022

Abstract

Aim: The purpose of the study is to compare the effectiveness of Atorvastatin and Rosuvastatin in cardiovascular disease patients.

Objectives:

• Comparision of Atorvastatin and Rosuvastatin in cardiovascular patients.
• Assessing and managing the cardiovascular disease.
• Monitoring the adverse effects, drug interactions, food interactions in cardiovascular disease patients.
• Assessing the complications and consequences reported by the patients.
• Counselling the cardiovascular patients about their disease and management.
• Compare the efficacy of equivalent doses of Rosuvastatin and Atorvastatin in lowering LDL –C levels.
• Compare the cost effectiveness of Rosuvastatin and Atorvastatin therapy.

Methodology: A prospective observational study was carried out at Departments of in and outpatients at Sai Srinivasa Hospital and Fathima Institute of Medical Sciences, for a period of 6 months (September 2018 to February 2019). All the patients who are diagnosed with cardiac problems were included in this study. Patients between ages of 30 - 70 yrs were considered. Patients with Pregnant, lactating, childrens, Diabetes Mellitus, Thyroid & Other than cardiovascular disease patients were excluded in the study.

Results: During the study 80 cases were recorded from SEP 2018 to FEB 2019 Among 80 patients, the incidence of CVD with hyperlipidemia was more at the age of 51-60 years in males. In the Atorvastatin group a decrease of 5.5% in LDL.C levels from that of base line mean LDL-C level was seen. In the Rosuvastatin group a decrease of 14.55% in LDL.C levels from that of base line mean LDL-C levels was seen, the difference in reduction being 9.0%.

In the Atorvastatin group there was 1.71% increase of HDL-C levels from that of mean base line HDL-C levels was seen. In the Rosuvastatin group the increase of HDL-C levels was only 0.4% from that of mean base line HDL-C levels. The difference in increase was more in Atorvastatin group, the difference being 1.31%.

 There was significant decrease in LDL –C level (P < 0.001) in Rosuvastatin group. So, this study shows that Rosuvastatin 10 mg/day is more effective than Atorvastatin 10 mg/day in lowering LDL-C levels in patients with Hypercholesterolemia.

Conclusion: Dyslipidemia is the most common co-morbid condition associated with cardiovascular disease.

The study was able to describe the comparative effect of Atorvastatin verses Rosuvastatin. Atorvastatin and Rosuvastatin have potent lipid lowering effect, but the spectrum of adverse effects is different in both the drugs. Hence Rosuvastatin is better to lower the LDL cholesterol than Atorvastatin. Atorvastatin is better to increase HDL cholesterol than Rosuvastatin, but both the drugs have their own limitations. So, by comparing the effect of both drugs, Rosuvastatin was recommended for patients having Hepato-toxicity disorders. Atorvastatin was recomended for patients who had complaints of myopathy.

This study shows that Rosuvastatin is more cost effective compared to Atorvastatin.

Keywords: Hyperlipidemia; CVD; Lipid Profile

References

1. Yadav KD and Wagle RR. “Knowledge and attitude regarding major risk factors of cardiovascular diseases among 15 - 19-year-old students of kathmandu district 11 (2012).
2. Furico colivicchi., et al. “Impact of treatment with rosuvastatin and atorvastatin on cardiovascular out comes: evidence from the archimedes-simulated clinical trails” 7 (2015): 555-565.
3. Sushant Khurana., et al. “Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome”. Journal of Pharmacology and Pharmacotherapeutics (2015).
4. Joseph T Dipiro. “Pharmacotherapeutic hand book -7^th edition 60.
5. Gianna Fabbri. “Aldo Pietro Maggioni, Cardiovascular risk reduction:What do recent trails with rosuvastatin tell us (2009).
6. Anne Waugh., et al. “Anatomy and physiology in health and illness 12th edition (international edition) 128.
7. Joseph T Dipiro. “Pharmacotherapeutic hand book,7^th – edition 143.
8. Gerard J Tortara. “Principles of anatomy and physiology 13^th-edition, volume 2 795.
9. Akhilendran R., et al. “Comparative efficacy of rosuvastatin and atorvastatin in patients with coronary artery disease”. European Journal of Pharmacuetical and Medical Research9 (2016): 312-316.
10. Mathew George., et al. “A comparative study on the effect of atorvastatin and rosuvastatin on cholesterol level and liver enzyme elevation in patients undergoing CABG, International Journal of pharmaceutical sciences review and research 51.2 (2018): 116-121.
11. Azan S Binbrek., et al. “Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice:A randomized,open-label,parallel-group multicenter study(DISCOVERY Alpha study), 2006,current therapuetic research volume 67 (2006): 21-43.
12. Jaakko Tuomiletho Rosuvastatin. “The most efficient treatment option for patients with dyslipidemia, future lipidol 2.2 (2007): 127-141.
13. Robert S Rosenson., et al. “Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome”. Diabetic Care (2009): 1087-1091.
14. Javed Ansari and Davinder Kaur. “A textbook of medical surgical and nursing 1 822.
15. Gerard J Tortara. “Principles of anatomy and physiology,13^th edition, volume-2 796.
16. Javed Ansari and Davinder Kaur. “A textbook of Medical surgical and Nursing 1 823-824.
17. Alfred Goodman Gilman. “The pharmacological basis of therapeutics ,10^th edition 46.
18. Gerard J Tortara. “Principles of anatomy and physiology, 13^th edition, volume-2 771.
19. Patel Ramesh., et al. “Evaluation of drug utilization pattern in patient of myocardial infarction and prevalence of MI by comparison of Age, sex, diet, smokers and non-smokers, alcoholic and non-alcoholic”. American Journal of Pharmacology and Pharmacotherapeutics1 (2015): 72-80.
20. Jean-Marc Labblanchea., et al. “Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apoliprotien B/apoliprotien A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study”. Archives of Cardiovascular Disease 103 (2010): 160-169.
21. Joseph T Dipiro. “Pharmacotherapeutics handbook, 7^th edition 82.
22. Bertram G. “Katzung, Basic and clinical pharmacology 10^th edition 198-200.
23. Churchill Livingstone Elsiver, Davidsons principles and practice of medicine -22^nd edition 267.
24. Robert H Nelson. “Hyperlipidemia as a risk factor for cardio vascular disease 40.1 (2013): 195-211.
25. Camelia Stancu and Anca Sima. “Statins: Mechanism of action and effects, “Nicolae Simionescu” Institute of cellular biology and pathology Romania 5 (2001): 378-387.
26. Michael B Clearfield., et al. “Comparison of the efficacy and safety of rosuvastatin 10mg and atorvastatin 20mg in high risk patients with hypercholesterolemia-prospective study to evaluate the use of low doses of the statins atorvastatin and rosuvastatin (PULSAR) (2006): 1-11.
27. John GF Cleland., et al. “Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure:prediction of cardiovascular events and interaction with the effects of rosuvastatin Journal of American college of pharmacy (2009): 54.
28. Adam Oesterle., et al. “Pleiotropic effects of statins on the cardiovascular system 120 (2016): 229-243.
29. KD Tripathi MD. “Essentials of medical pharmacology 7^th edition 635-637.
30. Tara V Shanbhag. pharmacology textbook 135.
31. Ahai Luvai., et al. “Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease 6 (2012): 17-33.
32. Dennis W Schneck., et al. “Comparative effect of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease”. American Journal of Cardiology 91 (2003): 33-41.
33. John Kjekshus., et al. “Rosuvstain in older patients with systolic heart failure”. The New Journal of Medicine 357 (2007): 48-61.
34. Peter H Jones., et al. “Comparison of the efficacy and safety of rosuvastatin versus atorvastatin,simvastatin,and pravastatin across doses(STELLAR TRAIL)”. American Journal of Cardiology 93 (2003):152-160.
35. Dani Feldman. A Textbook of Internal medicine-B 85.
36. Bertram G Katzung. “Basic and clinical pharmacology, 10^th edition 183.
37. Maria Angeles Alonso Garcia, guidelines on the management of stable Angina pectoris of European society of cardiology 06.

Citation

Citation: Sravan Kumar. “Comparative Effect of Atorvastatin and Rosuvastatin in cardiovascular Diseased patients". Acta Scientific Pharmaceutical Sciences 6.3 (2022): 02-08.

Copyright

Copyright: © 2022 Sravan Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.